MedPath

Single Pass Albumin Dialysis in Patients With Cirrhosis

Phase 1
Completed
Conditions
Cirrhosis
Encephalopathy
Acute on Chronic Hepatic Failure
Hepatorenal Syndrome
Interventions
Device: Single pass albumin dialysis
Registration Number
NCT00764049
Lead Sponsor
Assistance Publique - H么pitaux de Paris
Brief Summary

The aim of this study is to determine whether a simplified device of albumin dialysis also has beneficial effects.

Detailed Description

Albumin dialysis has beneficial effects in patients with acute on chronic liver failure. However, current devices are complex and costly. The aim of this study is to determine whether a simplified device of albumin dialysis also has beneficial effects.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
11
Inclusion Criteria
  • Minimum age of 18 years
  • Written consent after information of the patient or, in case of inability, by a parent or a close if he is present.
  • Patient having a cirrhosis researched by previous exams (liver biopsy) or, in the absence of previous diagnosis, diagnosed in view of the results of clinical, biological and morphological data, whatever the origin of the cirrhosis (virus of hepatitis B, virus of hepatitis C, extreme consumption of alcohol or other reasons)
Read More
Exclusion Criteria
  • Participation to an other study in the 4 weeks before
  • Active digestive bleeding, unchecked by the pharmacological treatments and the endoscopic techniques.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
1: Single pass albumin dialysisSingle pass albumin dialysisPatients entered in the pilot study.
Primary Outcome Measures
NameTimeMethod
Effects on clinical and biochemical variables3 months follow-up
Secondary Outcome Measures
NameTimeMethod
Safety3 months

Trial Locations

Locations (1)

H么pital Beaujon

馃嚝馃嚪

Clichy, France

漏 Copyright 2025. All Rights Reserved by MedPath